产品
编 号：F719471
分子式：C21H17N3O2
分子量：343.38
分子式：C21H17N3O2
分子量：343.38
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1623416-31-8
产品详情
生物活性：
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects.
体内研究：
AG-636 (10-100 mg/kg；灌胃；每天两次；持续 14 天) 处理可在 OCILY19 DLBCL 肿瘤异种移植模型中产生强烈的肿瘤生长抑制。Animal Model:Transgenic female 6-8-week-old CB17/Icr-Prkdcscid/IcrIcoCrl (CB17 SCID) mice injected with OCILY19 cells
Dosage:10 mg/kg, 30 mg/kg, or 100 mg/kg
Administration:Oral gavage; twice daily; for 14 days
Result:Resulted in robust tumor growth inhibition in xenograft lymphoma tumor models.
体外研究：
AG-636 在血液肿瘤和实体肿瘤来源的癌细胞系中具有很强的生长抑制活性。
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects.
体内研究：
AG-636 (10-100 mg/kg；灌胃；每天两次；持续 14 天) 处理可在 OCILY19 DLBCL 肿瘤异种移植模型中产生强烈的肿瘤生长抑制。Animal Model:Transgenic female 6-8-week-old CB17/Icr-Prkdcscid/IcrIcoCrl (CB17 SCID) mice injected with OCILY19 cells
Dosage:10 mg/kg, 30 mg/kg, or 100 mg/kg
Administration:Oral gavage; twice daily; for 14 days
Result:Resulted in robust tumor growth inhibition in xenograft lymphoma tumor models.
体外研究：
AG-636 在血液肿瘤和实体肿瘤来源的癌细胞系中具有很强的生长抑制活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备